麦克森McKesson Corporation (MCK) 2010年年度报告「NYSE」.pdf

《麦克森McKesson Corporation (MCK) 2010年年度报告「NYSE」.pdf》由会员分享，可在线阅读，更多相关《麦克森McKesson Corporation (MCK) 2010年年度报告「NYSE」.pdf（128页珍藏版）》请在三个皮匠报告上搜索。

1、Annual ReportFiscal Year Ended March 31,2010“In fi scal 2010,McKesson continued its track record of delivering outstanding stockholder returns.”John H.HammergrenChairman,President and Chief Executive Offi cer McKesson CorporationFinancial Results*Assumes$100 invested in McKessons common stock and in

2、 each index on March 31,2005,and reinvestment of all dividends.*Diluted earnings per share(“EPS”)excludes adjustments for litigation charges(credits),net.For supplemental fi nancial data and corresponding reconciliation to U.S.generally accepted accounting principles(“GAAP”),see Appendix A to this 2

3、010 Annual Report.Non-GAAP measures should be viewed in addition to,and not as an alternative for,fi nancial results prepared in accordance with GAAP.Rarely in our 177-year history has the Company experienced an era like the present one that offers so many opportunities for success and growth in the

4、 healthcare industry,while presenting so many questions about the path forward.An important lesson to be learned from our longand successful history is that change presents opportunities,and I can say with confidence that we are well positioned to thrive in the years ahead.Five factors support my po

5、sitive outlook for fiscal 2011 and beyond:1.Expanding Market for Pharmaceuticals and Medical SuppliesIn addition to the demographic shifts driving long-term demand for pharmaceuticals,thepharmaceutical market is expected to expand in thecoming years due to the new Patient Protection andAffordable Ca

6、re Act,which will add approximately 32 million new patients to the healthcare system overthe next decade.The legislation also seeks to lowerhealthcare costs,and pharmaceuticals offer one of the most cost-effective ways to treat many illnesses and chronic conditions.As the nations leading distributor